FindTrial
Sign In

intravenous immunoglobulin therapy

BIOLOGICAL5 trials

Sponsors

Masahiro Ishii, Maastricht University Medical Center, ECOG-ACRIN Cancer Research Group, University of Health Sciences Lahore, Hoffmann-La Roche

Conditions

Covid19Guillain-Barré SyndromeHeart FailureHematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmSteroid-Refractory Pneumonitisrefractory Kawasaki disease

Phase 1

IVIg Therapy for Patients With Idiopathic Cardiomyopathy and Endomyocardial Biopsy Proven High PVB19 Viral Load
NCT00659386
Maastricht University Medical CenterHeart Failure
Start: 2009-02-28End: 2010-08-31Target: 40Updated: 2009-02-04

Phase 2

Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis
TerminatedNCT04438382
ECOG-ACRIN Cancer Research GroupHematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Steroid-Refractory Pneumonitis
Start: 2021-01-07End: 2023-12-21Updated: 2026-04-02

Phase 3

Intravenous Immunoglobulins for the Treatment of Covid-19 Patients: a Clinical Trial
NCT04548557
University of Health Sciences LahoreCovid19
Start: 2020-09-15End: 2020-11-15Target: 60Updated: 2020-09-14
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)
WithdrawnNCT05494619
Hoffmann-La RocheGuillain-Barré Syndrome
Start: 2022-11-30End: 2026-09-30Updated: 2022-12-15

Unknown Phase

a methylprednisolone-plus-intravenous immunoglobulin combination therapy for Refractory Kawasaki Disease
Active, not recruitingJPRN-UMIN000005022
Masahiro Ishiirefractory Kawasaki disease
Start: 2007-04-01Target: 120Updated: 2025-07-18